1
|
Mohanto N, Park YJ, Jee JP. Current perspectives of artificial oxygen carriers as red blood cell substitutes: a review of old to cutting-edge technologies using in vitro and in vivo assessments. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2023; 53:153-190. [PMID: 35935469 PMCID: PMC9344254 DOI: 10.1007/s40005-022-00590-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 07/02/2022] [Indexed: 01/06/2023]
Abstract
Background Several circumstances such as accidents, surgery, traumatic hemorrhagic shock, and other causalities cause major blood loss. Allogenic blood transfusion can be resuscitative for such conditions; however, it has numerous ambivalent effects, including supply shortage, needs for more time, cost for blood grouping, the possibility of spreading an infection, and short shelf-life. Hypoxia or ischemia causes heart failure, neurological problems, and organ damage in many patients. To address this emergent medical need for resuscitation and to treat hypoxic conditions as well as to enhance oxygen transportation, researchers aspire to achieve a robust technology aimed to develop safe and feasible red blood cell substitutes for effective oxygen transport. Area covered This review article provides an overview of the formulation, storage, shelf-life, clinical application, side effects, and current perspectives of artificial oxygen carriers (AOCs) as red blood cell substitutes. Moreover, the pre-clinical (in vitro and in vivo) assessments for the evaluation of the efficacy and safety of oxygen transport through AOCs are key considerations in this study. With the most significant technologies, hemoglobin- and perfluorocarbon-based oxygen carriers as well as other modern technologies, such as synthetically produced porphyrin-based AOCs and oxygen-carrying micro/nanobubbles, have also been elucidated. Expert opinion Both hemoglobin- and perfluorocarbon-based oxygen carriers are significant, despite having the latter acting as safeguards; they are cost-effective, facile formulations which penetrate small blood vessels and remove arterial blockages due to their nano-size. They also show better biocompatibility and longer half-life circulation than other similar technologies.
Collapse
Affiliation(s)
- Nijaya Mohanto
- College of Pharmacy, Chosun University, 309 Pilmun-daero, Dong-gu, Gwangju, 61452 Republic of Korea
| | - Young-Joon Park
- College of Pharmacy, Ajou University, Suwon, Gyeonggi, Republic of Korea
| | - Jun-Pil Jee
- College of Pharmacy, Chosun University, 309 Pilmun-daero, Dong-gu, Gwangju, 61452 Republic of Korea
| |
Collapse
|
2
|
Taguchi K, Chuang VTG, Maruyama T, Otagiri M. Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications. J Pharm Sci 2012; 101:3033-46. [PMID: 22573538 DOI: 10.1002/jps.23181] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2012] [Revised: 04/12/2012] [Accepted: 04/18/2012] [Indexed: 12/15/2022]
Abstract
Human serum albumin is the most abundant protein in the blood. It is clinically used in the treatment of severe hypoalbuminemia and as a plasma expander. The use of albumins as a carrier for drugs is currently being developed, and some are now in the preclinical and clinical trial stages. The main technologies for utilizing an albumin as a drug carrier are protein fusion, polymerization and surface modification, and so on. Among these technologies, albumin dimerization has wide clinical applications as a plasma expander as well as a drug carrier. Despite the fact that many reports have appeared on drugs using an albumin dimer as a carrier, our knowledge of the characteristics of the albumin dimer itself is incomplete. In this review, we summarize the structural characteristics of recombinant albumin dimers produced by two methods, namely, chemical linkage with 1,6-bis(maleimido)hexane and genetically linked with an amino acid linker, and the physicochemical characteristics and biological properties of these preparations. Finally, the potential for pharmaceutical applications of albumin dimers in clinical situations is discussed.
Collapse
Affiliation(s)
- Kazuaki Taguchi
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan
| | | | | | | |
Collapse
|
3
|
Zhang YX, Chen CW, Wang M, Wei SS, Guan H, Chi TT, Qi XZ, Hu WT. Purification and characterization of albumin from frog skin of Duttaphrynus melanostictus. Protein J 2011; 30:464-70. [PMID: 21858423 DOI: 10.1007/s10930-011-9349-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Following determination of trypsin inhibitory activity, a serine protease inhibitor was purified and characterized from frog Duttaphrynus melanostictus serum. It was identified as serum albumin, with molecular weight of 67 kDa (DmA-serum). Different from bovine serum albumin, DmA-serum potently inhibited trypsin with similar K(i) values around 1.6 × 10⁻⁷ M. No inhibitory effect on thrombin, chymotrypsin, elastase and subtilisin was observed under the assay conditions. The N-terminal amino acid is EAEPHSRI. Subsequently, a protein with same N-terminal amino acid was purified from skin, termed as DmA-skin. However, DmA-skin is distinct from DmA-serum by binding of a haem b (0.5 mol/mol protein), and with low trypsin inhibitory activity. Frog albumin is distributed in frog skin and exhibited trypsin inhibitory activity, suggesting that it plays important roles in skin physiological functions, like water economy, metabolite exchange and osmoregulation, etc.
Collapse
Affiliation(s)
- Ying-Xia Zhang
- Key Laboratory of Tropic Biological Resources, Minister of Education, Haikou 570228, China.
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Li TH, Jing XB, Huang YB. Synthesis of the hemoglobin-conjugated polymer micelles by click chemistry as the oxygen carriers. POLYM ADVAN TECHNOL 2011. [DOI: 10.1002/pat.1926] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
5
|
Kim HW, Greenburg AG. Toward 21st Century Blood Component Replacement Therapeutics: Artificial Oxygen Carriers, Platelet Substitutes, Recombinant Clotting Factors, and Others. ACTA ACUST UNITED AC 2009; 34:537-50. [PMID: 17090427 DOI: 10.1080/10731190600973725] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
In this brief overview, recent progress and current status of blood substitute research and development is summarized. Current blood substitute development efforts are focused on red blood cell substitutes but substitutes for platelets and other blood components are also in progress. Red cell substitutes currently in various stages of development are semi-synthetic or synthetic oxygen carriers that include "stealth" or "masked" red cells, hemoglobin-based oxygen carriers and perfluorocarbon-based oxygen carriers. Artificial platelets (or platelet substitutes) are in early stages of development and include human platelet fragments or particles of synthetic/semi-synthetic materials or recombinant human serum albumin coupled with platelet surface receptor fragments. Of note, some recombinant clotting factors (Factors VII, VIII, IX) have already been successfully developed and licensed for treatment of hemophilia. In addition, some future approaches and prospects of blood component replacement therapeutics are discussed.
Collapse
Affiliation(s)
- Hae Won Kim
- Brown University Medical School and The Miriam Hospital, Providence, Rhode Island, USA.
| | | |
Collapse
|
6
|
Tsuchida E, Sou K, Nakagawa A, Sakai H, Komatsu T, Kobayashi K. Artificial Oxygen Carriers, Hemoglobin Vesicles and Albumin−Hemes, Based on Bioconjugate Chemistry. Bioconjug Chem 2009; 20:1419-40. [DOI: 10.1021/bc800431d] [Citation(s) in RCA: 126] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Eishun Tsuchida
- Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan, PRESTO, Japan Science and Technology Agency (JST), and Department of General Thoracic Surgery, School of Medicine, Keio University, Tokyo 160-8582, Japan
| | - Keitaro Sou
- Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan, PRESTO, Japan Science and Technology Agency (JST), and Department of General Thoracic Surgery, School of Medicine, Keio University, Tokyo 160-8582, Japan
| | - Akito Nakagawa
- Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan, PRESTO, Japan Science and Technology Agency (JST), and Department of General Thoracic Surgery, School of Medicine, Keio University, Tokyo 160-8582, Japan
| | - Hiromi Sakai
- Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan, PRESTO, Japan Science and Technology Agency (JST), and Department of General Thoracic Surgery, School of Medicine, Keio University, Tokyo 160-8582, Japan
| | - Teruyuki Komatsu
- Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan, PRESTO, Japan Science and Technology Agency (JST), and Department of General Thoracic Surgery, School of Medicine, Keio University, Tokyo 160-8582, Japan
| | - Koichi Kobayashi
- Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan, PRESTO, Japan Science and Technology Agency (JST), and Department of General Thoracic Surgery, School of Medicine, Keio University, Tokyo 160-8582, Japan
| |
Collapse
|
7
|
Komatsu T, Nakagawa A, Qu X. Structural and Mutagenic Approach to Create Human Serum Albumin-Based Oxygen Carrier and Photosensitizer. Drug Metab Pharmacokinet 2009; 24:287-99. [DOI: 10.2133/dmpk.24.287] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Abstract
In this brief review, basic principles and recent progresses on the development of therapeutic substitutes for major blood components are briefly discussed with primary focus on the red cell substitutes.
Collapse
|
9
|
Komatsu T, Huang Y, Wakamoto S, Abe H, Fujihara M, Azuma H, Ikeda H, Yamamoto H, Horinouchi H, Kobayashi K, Tsuchida E. Influence of O2-carrying plasma hemoprotein “albumin-heme” on complement system and platelet activationin vitro and physiological responses to exchange transfusion. J Biomed Mater Res A 2007; 81:821-6. [PMID: 17236218 DOI: 10.1002/jbm.a.31016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Recombinant human serum albumin (HSA) including the synthetic iron(II)-porphyrin (FeP), albumin-heme (HSA-FeP), is a unique O(2)-carrying plasma hemoprotein as a red blood cell substitute. We have investigated the possible influence of HSA-FeP on the complement system and platelet activation in vitro. The amounts of the serum complement titer CH(50) and terminal complement complex SC5b-9 of human blood serum, incubated with HSA-FeP (10, 20, and 40 vol %), were almost the same as those of the corresponding samples with HSA. The effect of HSA-FeP on the platelet reactivity has been demonstrated by conformational changes in the membrane glycoprotein IIb/IIIa and surface expression of an alpha-granule membrane protein P-selectin. Platelet activation in response to the ADP-stimulation was not influenced by the presence of HSA-FeP. It can be concluded that the albumin-heme solution does not facilitate the immunological reaction and platelet activation. Moreover, a 20% exchange transfusion with HSA-FeP into anesthetized rats has been performed to evaluate the circulation and blood parameters for 6 h. Time course changes in all parameters showed features identical to the control group (without infusion) and HSA group.
Collapse
Affiliation(s)
- Teruyuki Komatsu
- Advanced Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Ruzié C, Even P, Boitrel B. Dioxygen binding of water-soluble iron(ii) porphyrins in phosphate buffer at room temperature. Org Biomol Chem 2007; 5:1601-4. [PMID: 17571190 DOI: 10.1039/b702998e] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Two water-soluble tris(2-aminoethylamine) (tren) capped iron porphyrins were synthesized. The stability of their dioxygen adducts was studied in phosphate buffer, leading to half-life times around 7 min for the oxygenated species.
Collapse
Affiliation(s)
- Christian Ruzié
- Université de Rennes1, Sciences Chimiques de Rennes, UMR CNRS 6226 (I.C.M.V.), 35042, Rennes Cedex, France
| | | | | |
Collapse
|
11
|
Komatsu T, Ohmichi N, Nakagawa A, Zunszain PA, Curry S, Tsuchida E. O2and CO Binding Properties of Artificial Hemoproteins Formed by Complexing Iron Protoporphyrin IX with Human Serum Albumin Mutants. J Am Chem Soc 2005; 127:15933-42. [PMID: 16277537 DOI: 10.1021/ja054819u] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The binding properties of O2 and CO to recombinant human serum albumin (rHSA) mutants with a prosthetic heme group have been physicochemically and kinetically characterized. Iron(III) protoporphyrin IX (hemin) is bound in subdomain IB of wild-type rHSA [rHSA(wt)] with weak axial coordination by Tyr-161. The reduced ferrous rHSA(wt)-heme under an Ar atmosphere exists in an unusual mixture of four- and five-coordinate complexes and is immediately autoxidized by O2. To confer O2 binding capability on this naturally occurring hemoprotein, a proximal histidine was introduced into position Ile-142 or Leu-185 by site-directed mutagenesis. A single mutant (I142H) and three double mutants (I142H/Y161L, I142H/Y161F, and Y161L/L185H) were prepared. Both rHSA(I142H/Y161L)-heme and rHSA(I142H/Y161F)-heme formed ferrous five-N-coordinate high-spin complexes with axial ligation of His-142 under an Ar atmosphere. These artificial hemoproteins bind O2 at room temperature. Mutation at the other side of the porphyrin, Y161L/L185H, also allowed O2 binding to the heme. In contrast, the single mutant rHSA(I142H)-heme could not bind O2, suggesting that removal of Y161 is necessary to confer reversible O2 binding. Laser flash photolysis experiments showed that the kinetics of CO recombination with the rHSA(mutant)-heme were biphasic, whereas O2 rebinding exhibited monophasic kinetics. This could be due to the two different geometries of the axial imidazole coordination arising from the two orientations of the porphyrin plane in the heme pocket. The O2 binding affinities of the rHSA(mutant)-heme were significantly lower than those of hemoglobin and myoglobin, principally due to the high O2 dissociation rates. Changing Leu-161 to Phe-161 at the distal side increased the association rates of both O2 and CO, which resulted in enhanced binding affinity.
Collapse
Affiliation(s)
- Teruyuki Komatsu
- Advanced Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan.
| | | | | | | | | | | |
Collapse
|
12
|
Komatsu T, Oguro Y, Nakagawa A, Tsuchida E. Albumin Clusters: Structurally Defined Protein Tetramer and Oxygen Carrier Including Thirty-Two Iron(II) Porphyrins. Biomacromolecules 2005; 6:3397-403. [PMID: 16283771 DOI: 10.1021/bm050454u] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Recombinant human serum albumin (rHSA) clusters have been synthesized and physicochemically characterized. Cross-linking between the Lys groups of the core albumin and a unique Cys-34 of the shell albumins with an N-succinimidyl-6-[3'-(2-pyridyldithio)propionamido]hexanoate produced the structurally defined rHSA trimer and tetramer. MALDI-TOF-MS showed a single peak with the triple and quadruple masses of rHSA. Their molar ellipticities and the isoelectric points (pI = 4.8) are all identical to those of the monomer, suggesting that the essential structures of the albumin units were intact. TEM observations demonstrated a uniform morphology of the rHSA tetramer with a diameter of 20-30 nm. The circulation half-life (tau1/2) of the 125I-labeled rHSA tetramer in rat (5.5 h) was significantly longer than that of the monomer (2.3 h) due to the low ratio of the distribution phase (alpha-phase). A total of 24 and 32 molecules of the synthetic iron(II) porphyrins (FePs) are incorporated into the hydrophobic cavities of the rHSA trimer and tetramer, respectively, producing huge artificial hemoproteins. These albumin-heme clusters can reversibly bind and release O2 under physiological conditions (37 degrees C, pH 7.3) and showed similar O2-binding properties (O2-binding affinity, association and dissociation rate constants) to those of the corresponding monomer. A large volume of O2 can be chemically dissolved into the albumin-heme cluster solutions relative to the monomeric rHSA-FeP when the molar concentration of the albumin scaffold is identical.
Collapse
Affiliation(s)
- Teruyuki Komatsu
- Advanced Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan.
| | | | | | | |
Collapse
|
13
|
Zhang YX, Lai R, Lee WH, Zhang Y. Frog albumin is expressed in skin and characterized as a novel potent trypsin inhibitor. Protein Sci 2005; 14:2469-77. [PMID: 16081656 PMCID: PMC2253475 DOI: 10.1110/ps.051551105] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
A novel potent trypsin inhibitor was purified and characterized from frog Bombina maxima skin. A full-length cDNA encoding the protein was obtained from a cDNA library constructed from the skin. Sequence analysis established that the protein actually comprises three conserved albumin domains. B.maxima serum albumin was subsequently purified, and its coding cDNA was further obtained by PCR-based cloning from the frog liver. Only two amino acid variations were found in the albumin sequences from the skin and the serum. However, the skin protein is distinct from the serum protein by binding of a haem b (0.95 mol/mol protein). Different from bovine serum albumin, B. maxima albumin potently inhibited trypsin. It bound tightly with trypsin in a 1:1 molar ratio. The equilibrium dissociation constants (KD) obtained for the skin and the serum proteins were 1.92 x 10(-9) M and 1.55 x 10(-9) M, respectively. B. maxima albumin formed a noncovalent complex with trypsin through an exposed loop formed by a disulfide bond (Cys53-Cys62), which comprises the scissile bond Arg58(P1)-His59(P1'). No inhibitory effects on thrombin, chymotrypsin, elastase, and subtilisin were observed under the assay conditions. Immunohistochemical study showed that B. maxima albumin is widely distributed around the membranes of epithelial layer cells and within the stratum spongiosum of dermis in the skin, suggesting that it plays important roles in skin physiological functions, such as water economy, metabolite exchange, and osmoregulation.
Collapse
Affiliation(s)
- Ying-Xia Zhang
- Department of Animal Toxicology, Kunming Institute of Zoology, The Chinese Academy of Sciences, Kunming, Yunnan 650223, China (PRC).
| | | | | | | |
Collapse
|
14
|
Komatsu T, Ishihara S, Tsuchida E, Nishide H, Morokuma C, Nakamura S. Heat-Resistant Oxygen-Carrying Hemoproteins Consist of Recombinant Xylanases and Synthetic Iron(II) Porphyrin. Biomacromolecules 2005; 6:1489-94. [PMID: 15877369 DOI: 10.1021/bm049255l] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Synthetic iron(II) porphyrin (FeP) is equivalently incorporated into recombinant Thermotoga maritima xylanase B (TMX; family F/10 of glycoside hydrolase), producing a heat-resistant artificial hemoprotein (TMX-FeP) that can bind and release oxygen (O(2)) in aqueous medium (pH 7.3, 25 degrees C) in the same manner as hemoglobin and myoglobin. The oxygenated species was sufficiently stable; the half-lifetime against the ferric state (tau(1/2)) was 5 h. This O(2)-carrying hemoprotein showed a high degree of thermal stability over a wide range of temperatures up to 90 degrees C (tau(1/2) = 5 min at 90 degrees C and 9 min at 75 degrees C). Dictyoglomus thermophilum xylanase B (DTX; family G/11) also incorporates FeP, and DTX-FeP showed identical O(2)-binding parameters and thermostability. TMX-FeP is capable of catalyzing the beta-1,4-d-xylan hydrolysis reaction. Its larger K(m) value compared to that of TMX itself suggested competitive FeP binding to the active site of the host enzyme.
Collapse
Affiliation(s)
- Teruyuki Komatsu
- Department of Applied Chemistry and Advanced Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan
| | | | | | | | | | | |
Collapse
|
15
|
Safety and Efficacy of Hemoglobin-Vesicles and Albumin-Hemes. ARTIFICIAL OXYGEN CARRIER 2005. [PMCID: PMC7123142 DOI: 10.1007/4-431-26651-8_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Tsuchida E, Sakai H, Komatsu T, Takeoka S, Huang Y, Sou K, Nakagawa A, Teramura Y, Kobayashi K. Oxygen infusions (hemoglobin-vesicles and albumin-hemes) based on nano-molecular sciences. POLYM ADVAN TECHNOL 2005. [DOI: 10.1002/pat.559] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
17
|
Komatsu T, Oguro Y, Teramura Y, Takeoka S, Okai J, Anraku M, Otagiri M, Tsuchida E. Physicochemical characterization of cross-linked human serum albumin dimer and its synthetic heme hybrid as an oxygen carrier. Biochim Biophys Acta Gen Subj 2004; 1675:21-31. [PMID: 15535964 DOI: 10.1016/j.bbagen.2004.08.010] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2004] [Revised: 08/09/2004] [Accepted: 08/10/2004] [Indexed: 11/17/2022]
Abstract
The recombinant human serum albumin (rHSA) dimer, which was cross-linked by a thiol group of Cys-34 with 1,6-bis(maleimido)hexane, has been physicochemically characterized. Reduction of the inert mixed-disulfide of Cys-34 beforehand improved the efficiency of the cross-linking reaction. The purified dimer showed a double mass and absorption coefficient, but unaltered molar ellipticity, isoelectric point (pI: 4.8) and denaturing temperature (65 degrees C). The concentration dependence of the colloid osmotic pressure (COP) demonstrated that the 8.5 g dL(-1) dimer solution has the same COP with the physiological 5 g dL(-1) rHSA. The antigenic epitopes of the albumin units are preserved after bridging the Cys-34, and the circulation lifetime of the 125I-labeled variant in rat was 18 h. A total of 16 molecules of the tetrakis[(1-methylcyclohexanamido)phenyl]porphinatoiron(II) derivative (FecycP) is incorporated into the hydrophobic cavities of the HSA dimer, giving an albumin-heme hybrid in dimeric form. It can reversibly bind and release O2 under physiological conditions (37 degrees C, pH 7.3) like hemoglobin or myoglobin. Magnetic circular dichroism (CD) revealed the formation of an O2-adduct complex and laser flash photolysis experiments showed the three-component kinetics of the O2-recombination reaction. The O2-binding affinity and the O2-association and -dissociation rate constants of this synthetic hemoprotein have also been evaluated.
Collapse
Affiliation(s)
- Teruyuki Komatsu
- Advanced Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Huang Y, Komatsu T, Yamamoto H, Horinouchi H, Kobayashi K, Tsuchida E. Safety Evaluation of an Artificial O2 Carrier as a Red Blood Cell Substitute by Blood Biochemical Tests and Histopathology Observations. ASAIO J 2004; 50:525-9. [PMID: 15672783 DOI: 10.1097/01.mat.0000144361.60280.da] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Recombinant human serum albumin (rHSA) incorporating synthetic heme with a covalently linked proximal base (albumin-heme [rHSA-hemel) is an artificial O2 carrier that can transport O2 like hemoglobin does in the blood stream. To evaluate the clinical safety of this compound, 20% and 40% exchange transfusions with rHSA-heme into anesthetized rats were followed by blood biochemical tests and histopathologic observations for 7 days. In the 20% rHSA-heme group, a total of 30 analytes by blood biochemical tests showed almost the same values as those observed in the reference 20% rHSA group. Although some abnormal values for liver parameters were found in the 40% rHSA-heme group, they returned to normal after 7 days. Histopathologic observations indicated that the administration of rHSA-heme in a volume of 20% total blood volume did not produce any negative side effects on the vital organs.
Collapse
Affiliation(s)
- Yubin Huang
- Advanced Research Institute for Science and Engineering, Waseda University, Shinjuku-ku, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
19
|
Kim HW, Greenburg AG. Artificial Oxygen Carriers as Red Blood Cell Substitutes: A Selected Review and Current Status. Artif Organs 2004; 28:813-28. [PMID: 15320945 DOI: 10.1111/j.1525-1594.2004.07345.x] [Citation(s) in RCA: 105] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Two distinct approaches are being explored in red blood cell substitute (RCS) development: hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon-based oxygen carriers (PFBOCs). HBOCs are based on intra- and/or intermolecularly "engineered" human or animal hemoglobins (Hbs), optimized for O2 delivery and longer intravascular circulation. Some are currently being evaluated in Phase II/III clinical studies. PFBOCs are aqueous emulsions of perfluorocarbon derivatives that dissolve relatively large amounts of O2. A PFBOC based on a 60% (wt/vol) emulsion of perfluorooctyl bromide has been evaluated in Phase II/III clinical trials. Although current PFBOC products generally require patients to breathe O2 enriched air, they render certain advantages since they are totally synthetic. This article provides a short review of the basic principles, approaches, and current status of RCS development. Results of preclinical and clinical studies including recent Phase II/III clinical studies are discussed.
Collapse
Affiliation(s)
- Hae Won Kim
- Department of Surgery, Brown University Medical School, The Miriam Hospital, Providence, RI 02906, USA.
| | | |
Collapse
|
20
|
Komatsu T, Yamamoto H, Huang Y, Horinouchi H, Kobayashi K, Tsuchida E. Exchange transfusion with synthetic oxygen-carrying plasma protein ?albumin-heme? into an acute anemia rat model after seventy-percent hemodilution. ACTA ACUST UNITED AC 2004; 71:644-51. [PMID: 15514927 DOI: 10.1002/jbm.a.30200] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Recombinant human serum albumin (rHSA) incorporating the synthetic heme "albumin-heme" is an oxygen-carrying plasma protein that has the potential to be a red blood cell substitute. The physiological responses to a 30% exchange transfusion with two types of albumin-heme (rHSA-FecycP, rHSA-FepivP) solutions after 70% isovolemic hemodilution with 5 g/dL rHSA were investigated using anesthetized rats. The circulation parameters, blood parameters, renal cortical oxygen pressure (pO2), and muscle tissue pO2 were carefully monitored for 60 min after the injection. The declined mean arterial pressure and the mixed venous partial pO2 significantly recovered to 70.8 and 91.9% of the basal values by intravenous infusion of albumin-hemes, respectively. The lowered renal cortical pO2 also increased, indicating oxygen transport by this synthetic hemoprotein. The administration of albumin-heme into the acute anemia rat model after hemorrhage improved the circulatory volume and resuscitated the shock state. Both rHSA-FecycP and rHSA-FepivP transported oxygen through the body.
Collapse
Affiliation(s)
- Teruyuki Komatsu
- Advanced Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan
| | | | | | | | | | | |
Collapse
|
21
|
Huang Y, Komatsu T, Yamamoto H, Horinouchi H, Kobayashi K, Tsuchida E. Exchange transfusion with entirely synthetic red-cell substitute albumin-heme into rats: Physiological responses and blood biochemical tests. ACTA ACUST UNITED AC 2004; 71:63-9. [PMID: 15368255 DOI: 10.1002/jbm.a.30127] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Recombinant human serum albumin (rHSA) incorporating 2-[8-[N-(2-methylimidazolyl)]octanoyloxymethyl]-5,10,15,20-[tetrakis[alpha,alpha,alpha,alpha-o-(1-methylcyclohexanoyl)amino]phenyl]porphinatoiron(II) [albumin-heme (rHSA-heme)] is an artificial hemoprotein which has the capability to transport O(2) in vitro and in vivo. A 20% exchange transfusion with rHSA-heme into anesthetized rats has been performed to evaluate its clinical safety by monitoring the circulation parameters and blood parameters for 6 h after the infusion. Time course changes in all parameters essentially showed the same features as those of the control group (without infusion) and rHSA group (with administration of the same amount of rHSA). Blood biochemical tests of the withdrawn plasma at 6 h after the exchange transfusion have also been carried out. No significant difference was found between the rHSA-heme and rHSA groups, suggesting the initial clinical safety of this entirely synthetic O(2)-carrier as a red-cell substitute.
Collapse
Affiliation(s)
- Yubin Huang
- Advanced Research Institute for Science and Engineering, Waseda University,3-4-1 Okubo, Shinjuku, Tokyo 169-8555, Japan
| | | | | | | | | | | |
Collapse
|
22
|
Crystal structure and reactivity of a five-coordinate chloroiron(III) complex with a bulky tetradentate Schiff base ligand. Inorganica Chim Acta 2003. [DOI: 10.1016/s0020-1693(03)00311-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
23
|
Huang Y, Komatsu T, Nakagawa A, Tsuchida E, Kobayashi S. Compatibility in vitro of albumin-heme (O(2) carrier) with blood cell components. J Biomed Mater Res A 2003; 66:292-7. [PMID: 12888999 DOI: 10.1002/jbm.a.10573] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Recombinant human serum albumin including 2-[8-[N-(2-methylimidazolyl)]octanoyloxymethyl]-5,10,15,20-tetrakis(alpha,alpha,alpha,alpha-o-pivaloylamino)phenylporphinatoiron(II) (albumin-heme; rHSA-FeP) is a synthetic hemoprotein that has sufficient capability to reversibly bind and release O(2) under physiological conditions (pH 7.3, 37 degrees C) similar to hemoglobin and myoglobin. In order to use this albumin-based O(2) carrier as a new class of red blood cell substitutes, its compatibility with blood cell components carefully was investigated in vitro. After the addition of the rHSA-FeP solution into whole blood at 10, 20, and 44 vol %, the FeP concentration in the plasma phase remained constant for 6 h at 37 degrees C in each group, and no significant time dependence was observed in the numbers of red blood cells, white blood cells, or platelets. The microscopic observations clearly showed that the shapes of the red blood cells had not been deformed during the measurement period. With respect to the blood coagulation parameters (prothrombin time and activated partial thromboplastin time), the coexistence of rHSA-FeP had only a negligibly small influence. Also the blood compatibility under dynamic flow conditions was evaluated using a microchannel array flow analyzer. All these results suggest that the albumin-heme has no effect on the morphology of blood cell components in vitro.
Collapse
Affiliation(s)
- Yubin Huang
- Advanced Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan
| | | | | | | | | |
Collapse
|
24
|
Zunszain PA, Ghuman J, Komatsu T, Tsuchida E, Curry S. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC STRUCTURAL BIOLOGY 2003; 3:6. [PMID: 12846933 PMCID: PMC166163 DOI: 10.1186/1472-6807-3-6] [Citation(s) in RCA: 374] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2003] [Accepted: 07/07/2003] [Indexed: 11/10/2022]
Abstract
BACKGROUND Human serum albumin (HSA) is an abundant plasma protein that binds a wide variety of hydrophobic ligands including fatty acids, bilirubin, thyroxine and hemin. Although HSA-heme complexes do not bind oxygen reversibly, it may be possible to develop modified HSA proteins or heme groups that will confer this ability on the complex. RESULTS We present here the crystal structure of a ternary HSA-hemin-myristate complex, formed at a 1:1:4 molar ratio, that contains a single hemin group bound to subdomain IB and myristate bound at six sites. The complex displays a conformation that is intermediate between defatted HSA and HSA-fatty acid complexes; this is likely to be due to low myristate occupancy in the fatty acid binding sites that drive the conformational change. The hemin group is bound within a narrow D-shaped hydrophobic cavity which usually accommodates fatty acid; the hemin propionate groups are coordinated by a triad of basic residues at the pocket entrance. The iron atom in the centre of the hemin is coordinated by Tyr161. CONCLUSION The structure of the HSA-hemin-myristate complex (PDB ID 1o9x) reveals the key polar and hydrophobic interactions that determine the hemin-binding specificity of HSA. The details of the hemin-binding environment of HSA provide a structural foundation for efforts to modify the protein and/or the heme molecule in order to engineer complexes that have favourable oxygen-binding properties.
Collapse
Affiliation(s)
- Patricia A Zunszain
- Department of Biological Sciences, Imperial College London, Room 746 Huxley Building, South Kensington Campus, London SW7 2AZ, United Kingdom
| | - Jamie Ghuman
- Department of Biological Sciences, Imperial College London, Room 746 Huxley Building, South Kensington Campus, London SW7 2AZ, United Kingdom
| | - Teruyuki Komatsu
- Advanced Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan
| | - Eishun Tsuchida
- Advanced Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan
| | - Stephen Curry
- Department of Biological Sciences, Imperial College London, Room 746 Huxley Building, South Kensington Campus, London SW7 2AZ, United Kingdom
| |
Collapse
|
25
|
Nakagawa A, Komatsu T, Ohmichi N, Tsuchida E. Synthetic Dioxygen-carrying Hemoprotein. Human Serum Albumin Including Iron(II) Complex of Protoporphyrin IX with an Axially Coordinated Histidylglycyl-propionate. CHEM LETT 2003. [DOI: 10.1246/cl.2003.504] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
26
|
Tsuchida E, Komatsu T, Matsukawa Y, Nakagawa A, Sakai H, Kobayashi K, Suematsu M. Human serum albumin incorporating synthetic heme: red blood cell substitute without hypertension by nitric oxide scavenging. J Biomed Mater Res A 2003; 64:257-61. [PMID: 12522812 DOI: 10.1002/jbm.a.10324] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The administration of extracellular, hemoglobin-based oxygen carriers often elicits an acute increase in blood pressure by vasoconstriction. This side effect is now recognized to be due to the depletion of nitric oxide (endothelial-derived relaxing factor) by the extravasuated hemoglobins. We have recently found that the administration of a recombinant human serum albumin (rHSA)-based oxygen carrier involving synthetic tetraphenyporphinatoiron(II) derivative (FeP) (rHSA-FeP) does not induce such hypertensive action, because of its low permeability through the vascular endothelium. The heart rate responses after the rHSA-FeP injection were also negligibly small. Visualization of the intestinal microcirculatory changes clearly revealed the widths of the venule and arteriole to be fairly constant. The entirely synthetic rHSA-FeP becomes a promising material as a new type of red blood cell substitute.
Collapse
Affiliation(s)
- Eishun Tsuchida
- Advanced Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan.
| | | | | | | | | | | | | |
Collapse
|
27
|
Tsuchida E, Komatsu T, Yanagimoto T, Sakai H. Preservation stability and in vivo administration of albumin-heme hybrid solution as an entirely synthetic O2-carrier. POLYM ADVAN TECHNOL 2003. [DOI: 10.1002/pat.240] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
28
|
Kobayashi K, Komatsu T, Iwamaru A, Matsukawa Y, Horinouchi H, Watanabe M, Tsuchida E. Oxygenation of hypoxic region in solid tumor by administration of human serum albumin incorporating synthetic hemes. J Biomed Mater Res A 2003; 64:48-51. [PMID: 12483695 DOI: 10.1002/jbm.a.10323] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Recombinant human serum albumin incorporating synthetic heme (rHSA-FeP) was tested for its ability to increase O(2) tension in the hypoxia of the solid tumor rat model. By the direct administration of the rHSA-FeP solution (10 mL/kg) via the aorta descendens to the ascites hepatoma LY80 tumor on the right femur, the O(2) tension of the hypoxic region immediately increased to 3.45 +/- 1.43 Torr, which corresponds to a 2.4-fold increase compared to that of the baseline value. These high O(2) levels continued for 300 s after the infusion. The rHSA-FeP solution can be utilized not only as a red blood cell substitute but also as an O(2)-carrying medicine for the effective reoxygenation of the hypoxia solid tumor.
Collapse
Affiliation(s)
- Koichi Kobayashi
- Department of General Thoracic Surgery, School of Medicine, Keio University, Tokyo 160-8582, Japan
| | | | | | | | | | | | | |
Collapse
|
29
|
Huang Y, Komatsu T, Tsuchida E. Microcalorimetry investigation of synthetic hemoprotein (albumin-heme). POLYM ADVAN TECHNOL 2003. [DOI: 10.1002/pat.418] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
30
|
Komatsu T, Ishihara S, Tsuchida E, Nishide H, Morokuma C, Nakamura S. Thermostable Synthetic Hemoproteins: Thermophilic Xylanases Hybridized with Dioxygen-Carryingmeso-Tetrakis(o-pivalamidophenyl)porphinatoiron(II) Derivative. CHEM LETT 2003. [DOI: 10.1246/cl.2003.108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
31
|
Affiliation(s)
- Stephen Curry
- Biophysics Section, Department of Biological Sciences, Blackett Laboratory, Imperial College of Science, Technology and Medicine, London, United Kingdom.
| |
Collapse
|
32
|
Chuang VTG, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002; 19:569-77. [PMID: 12069157 DOI: 10.1023/a:1015396825274] [Citation(s) in RCA: 198] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Gene manipulation techniques open up the possibility of making recombinant human serum albumin (rHSA) or mutants with desirable therapeutic properties and for protein fusion products. rHSA can serve as a carrier in synthetic heme protein, thus reversibly carrying oxygen. Myristoylation of insulin results in a prolonged half-life because of self aggregation and increased albumin binding. Preferential albumin uptake by tumor cells serves as the basis for albumin-anticancer drug conjugate formulation. Furthermore, drug targeting can be achieved by incorporating drugs into albumin microspheres whereas liver targeting can be achieved by conjugating drug with galactosylated or mannosylated albumin. Microspheres and nanoparticles of different sizes can, with or without drugs and/or radioisotopes, be used for drug delivery or diagnostic purposes. In vivo implantation of albumin fusion protein expressing cells encapsulated in HSA-alginate coated beads showed promising results compared to organoids in rats. Chimeric peptide strategy with cationized albumin as the transport can deliver drugs via receptor mediated transcytosis through the blood brain barrier. Gene bearing, albumin microbubbles containing ultrasound contrast agents can non-invasively deliver gene after destruction by ultrasound. Various site-directed mutants of HSA can be tailor made depending on the application required.
Collapse
|
33
|
Wardell M, Wang Z, Ho JX, Robert J, Ruker F, Ruble J, Carter DC. The atomic structure of human methemalbumin at 1.9 A. Biochem Biophys Res Commun 2002; 291:813-9. [PMID: 11866438 DOI: 10.1006/bbrc.2002.6540] [Citation(s) in RCA: 260] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The high resolution structure of hemalbumin was determined by single crystal X-ray diffraction to a resolution of 1.9 A. The structure revealed the protoporphyrin IX bound to a single site within a hydrophobic cavity in subdomain IB, one of the principal binding sites for long chain fatty acid. The iron is penta coordinated with the fifth ligand comprised of the hydroxyl oxygen of Tyr-161 (phenolic oxygen to heme plane distance: 2.73 A) in an otherwise completely hydrophobic pocket. The heme propionic acid residues form salt bridges with His-142 and Lys-190, which together with a series of hydrophobic interactions, enclose and secure the heme within the IB helical motif. A detailed discussion of the structure together with its implications for the development of potential blood substitutes is presented.
Collapse
Affiliation(s)
- Mark Wardell
- New Century Pharmaceuticals, Inc., 895 Martin Road, Huntsville, Alabama 35824, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
Wu Y, Komatsu T, Tsuchida E. Electrochemical studies of albumin–heme hybrid in aqueous media by modified electrode. Inorganica Chim Acta 2001. [DOI: 10.1016/s0020-1693(01)00579-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Komatsu T, Okada T, Moritake M, Tsuchida E. O2-Binding Properties of Double-Sided Porphinatoiron(II)s with Polar Substituents and Their Human Serum Albumin Hybrids. BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN 2001. [DOI: 10.1246/bcsj.74.1695] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
36
|
Wu Y, Komatsu T, Tsuchida E. Redox Behavior of Human Serum Albumin–Heme Hybrid on Graphite Electrode Modified with Didodecyldimethylammonium Bromide. CHEM LETT 2000. [DOI: 10.1246/cl.2000.1194] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
37
|
Komatsu T, Hamamatsu K, Tsuchida E. Cross-Linked Human Serum Albumin Dimer Incorporating Sixteen (Tetraphenylporphinato)iron(II) Derivatives: Synthesis, Characterization, and O2-Binding Property. Macromolecules 1999. [DOI: 10.1021/ma990826p] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Teruyuki Komatsu
- Department of Polymer Chemistry, Advanced Research Institute for Science & Engineering, Waseda University, Tokyo 169-8555, Japan
| | - Kazuyoshi Hamamatsu
- Department of Polymer Chemistry, Advanced Research Institute for Science & Engineering, Waseda University, Tokyo 169-8555, Japan
| | - Eishun Tsuchida
- Department of Polymer Chemistry, Advanced Research Institute for Science & Engineering, Waseda University, Tokyo 169-8555, Japan
| |
Collapse
|